-
Xu Jinghe meets with French ambassador to China
2025-03-26
Xu Jinghe, Deputy Commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by French Ambassador to China Bertrand Lortholary on March 18, to discuss enhancing cooperation in the cosmetics regulation.
-
Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Regulation of Drugs and Medical Devices to Promote the High-Quality Development of the Pharmaceutical Industry
2025-03-25
In order to thoroughly implement the important instructions and directives of General Secretary Xi Jinping on the regulation of drugs and medical devices and the development of the pharmaceutical industry, and to comprehensively deepen reforms in drug and medical device regulation to promote the high-quality development of the pharmaceutical industry, the following opinions are proposed with the approval of the State Council.
-
Measures facilitate approval of 48 first-in-class innovative drugs
2025-03-21
China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.
-
China approves 48 innovative drugs in 2024
2025-03-19
China approved 48 first-in-class innovative drugs in 2024, covering nearly 20 therapeutic areas, including oncology, neurological disorders, endocrine diseases and anti-infective medicines, according to a report released by the National Medical Products Administration on Tuesday.
-
Ebronucimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ebronucimab Injection (trade name: 伊喜宁) of Kangrong Dongfang (Guangdong) Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Iparomlimab and Tuvonralimab Injection Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Iparomlimab and Tuvonralimab Injection (trade name: 齐倍安) of Qilu Pharmaceuticals Co., Ltd. is approved for marketing with conditions by China NMPA. It is indicated for the treatment of recurrent or refractory cervix carcinoma patients who progressed on or after platinum-based chemotherapy.
